Background-Primary percutaneous coronary intervention, if performed promptly, is the preferred strategy to restore flow to the infarct-related artery in patients with ST-segment elevation myocardial infarction. We sought to determine whether eptifibatide, a platelet glycoprotein IIb/IIIa inhibitor, given before catheterization would improve clinical outcomes in patients referred for primary percutaneous coronary intervention. Methods and Results-We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg). The primary end point was a composite of death from any cause, recurrent myocardial infarction, or recurrent severe ischemia during the first 30 days after randomization. At 30 days, the primary end point was reached by 13 patients (6.47%) assigned to heparin plus eptifibatide and by 11 patients (5.53%) assigned to heparin alone (relative risk, 1.18; 95% CI, 0.52 to 2.70; Pϭ0.69). The rates of major or minor bleeding were higher in patients assigned to heparin plus eptifibatide than that in patients assigned to heparin alone ( 
A ctivated platelets play a major role in the cascade of events leading to ST-segment elevation myocardial infarction (STEMI). Hence, antiplatelet therapy has become an important adjunct in the management of STEMI. [1] [2] [3] [4] This is particularly relevant for patients undergoing primary percutaneous coronary intervention (PCI), where antiplatelet therapy may prevent thrombotic reocclusion of the infarct-related artery.
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Trials have shown that abciximab, a monoclonal antibody that inhibits the platelet glycoprotein IIb/IIIa receptor, reduces major cardiac adverse events in patients treated with primary PCI. [5] [6] [7] [8] [9] In 2 of these trials, benefits at long-term were sustained. 10, 11 Furthermore, a systematic overview of randomized trials reported that adjunctive treatment with abciximab improved survival at six months. 12 The evidence supporting the use of small-molecule glycoprotein IIb/IIIa inhibitors, such as eptifibatide, in patients with STEMI remains limited. Observational studies suggest that eptifibatide used during primary PCI yields clinical benefits similar to abciximab. [13] [14] [15] Compared with abciximab, eptifibatide is significantly cheaper. 13 One randomized trial concluded that in the setting of primary PCI, initiation of eptifibatide in the emergency department compared with that in the catheterization laboratory was safe and associated with superior angiographic results. 16 Given the common mode of action of platelet glycoprotein IIb/IIIa inhibitors, and the clinical experience to date, the current guidelines support the use of small-molecule glycoprotein IIb/IIIa inhibitors, such as eptifibatide or tirofiban, during primary PCI, with a class IIb recommendation. 17, 18 In patients with non-STEMI, the addition of the P2Y12 platelet receptor antagonist clopidogrel to aspirin before PCI improves early and late clinical outcomes. 19 Although there are limited data on the benefits of pretreatment with clopidogrel in the setting of acute PCI for STEMI, it had become practice in many institutions, including our own, to prescribe 600 mg of clopidogrel before the intervention. We, therefore, designed this study to assess the safety and efficacy of eptifibatide in patients referred for primary PCI who received a high-loading dose (600 mg) of clopidogrel at the time of hospital presentation.
Methods Trial
A Safety and Efficacy Study of Integrilin-Facilitated PCI Versus Primary PCI in ST-Elevation Myocardial Infarction (ASSIST) was a prospective, randomized trial that compared treatment with heparin plus eptifibatide to heparin alone in patients referred for primary PCI. The study was conducted in 3 Ottawa hospitals, with the interventional facility located at the University of Ottawa Heart Institute.
Patient Selection
Patients were eligible for enrollment if they presented within 12 hours of the onset of ischemic chest discomfort of at least 30 minutes duration and having Ն1 mm (0.1 mV) ST-elevation in 2 or more contiguous leads on a standard 12-lead ECG or left bundle branch block not known to be old. Exclusion criteria were active bleeding, stroke within 90 days, intracranial bleeding at any time, major surgery or trauma within 6 weeks, systolic blood pressure Ͼ200 mm Hg or diastolic blood pressure Ͼ110 mm Hg, prolonged cardiopulmonary resuscitation, PCI within 30 days, fibrinolytic agents within 7 days, any glycoprotein IIb/IIIa inhibitors within 7 days, low-molecular-weight heparin within 12 hours, coagulation disorder, current warfarin treatment, intolerance to aspirin or clopidogrel, other illness likely to result in death within 12 months, pregnancy, creatinine Ͼ200 mol/L, cardiogenic shock, and severe contrast allergy. The protocol was approved by the institutional review board at each hospital, and all patients provided informed consent.
Study Design
All patients received 160 mg of chewable aspirin, 600 mg of oral clopidogrel, and 60 U/kg of intravenous unfractionated heparin to a maximum dose of 4000 U, before catheterization. Patients were randomly assigned in a 1:1 ratio to PCI with heparin plus eptifibatide or to PCI with heparin alone, in blocks of 10 at each site. Immediately after randomization, patients assigned to the eptifibatide group received open-label drug, 180 g/kg of body weight bolus, followed by a continuous infusion of 2.0 g/kg per minute with a second bolus of 180 g/kg administered 10 minutes after the first bolus. The infusion was reduced to 1.0 g/kg per minute in patients with a creatinine clearance of Ͻ50 mL/min. Eptifibatide was to be initiated before cardiac catheterization, and the infusion continued for 18 hours after PCI.
Coronary angiography was performed using a nonionic contrast medium. It was suggested to perform PCI of the infarct-related artery only and to use Driver or Micro-Driver bare metal stents (Medtronic of Canada Ltd). As per guidelines, 20 additional doses of heparin were given during the procedure to achieve an activated clotting time of 200 s in patients assigned to heparin plus eptifibatide and an activated clotting time Ͼ250 s in patients assigned to heparin alone. The use of glycoprotein IIb/IIIa inhibitors in patients assigned to PCI with heparin alone was strongly discouraged but could be considered for "bailout" at the discretion of the operator, ie, large residual thrombus, Thrombolysis in Myocardial Infarction (TIMI) 21 grade flow Ͻ3 despite treatment with intracoronary adenosine, or abrupt vessel closure after stent deployment. Corrected TIMI frame counts and myocardial perfusion grades were evaluated by independentblinded investigators using previously described methodology. 22, 23 After catheterization, heparin was not routinely administered, and femoral sheaths were removed within 4 to 6 hours. Aspirin 81 to 325 mg daily was prescribed to be continued indefinitely along with clopidogrel 75 mg daily for at least 1 year. ␤-blockers, angiotensinconverting enzyme inhibitors, and lipid lowering drugs were prescribed according to guidelines. 20 After discharge, follow-up was obtained by telephone at 1 to 2 weeks and by a clinic visit at 30 days and at 6 months.
End Points and Definitions
The primary end point was a composite of death from any cause, recurrent myocardial infarction, or recurrent severe ischemia during the first 30 days after randomization. Reinfarction was defined by the presence of recurrent ischemic symptoms at rest, lasting at least 30 minutes and accompanied by any one of the following: (1) new or recurrent ST-segment elevation of Ն1 mm (0.1 mV) in any contiguous leads, (2) new left bundle branch block, or (3) reelevation in serum creatine kinase level more than twice the upper limit of normal and at least more than 50% of the lowest level measured postinfarction. Recurrent severe ischemia was defined as recurrent symptoms of ischemia at rest associated with any one of the following: (1) new ST-segment deviation (elevation at least 0.1 mV or depression Ͼ0.05 mV measured 80 ms after the J-point in at least 2 contiguous leads), (2) an episode of acute pulmonary edema, sustained ventricular arrhythmia, or hemodynamic instability, (3) the need for urgent revascularization within 30 days, or (4) recurrent myocardial infarction.
Secondary end points included stroke, congestive heart failure, and cardiogenic shock. Episodes of bleeding were classified by an independent adjudicator as major or minor according to the TIMI criteria. 24 A blinded, off-site, independent Clinical Event Committee (Cathy McLellan, chair, Waitak Kong, and Paul Malik, Queen's University, Kingston, Ontario, Canada) adjudicated all possible events related to the primary outcome. An independent Data Safety Monitoring Committee (Jean-Claude Tardif, chair, and Philippe L'Allier, Montreal Heart Institute, Montréal, Quebec, Canada) reviewed the data at regular intervals.
Statistical Analysis
Based on previous studies, 7,25 the incidence of the primary end point at 30 days in the group of patients assigned to heparin alone was estimated at 15% and in the group of patients assigned to heparin plus eptifibatide at 5%. In calculating sample size, we did not include studies where glycoprotein IIb/IIIa inhibitors were initiated in the catheterization laboratory, because less benefit was suggested from the available data. The sample size to detect a difference between 15% and 5.0%, with a level of significance of 0.05 and 90% power using a 2 test, was determined to be 187 patients per group. With an anticipated loss to follow-up rate of 5%, the minimum number of patients required was 200 per group.
All analyses on the primary end point and its components were performed on an intention-to-treat basis. Categorical variables were compared by Fisher exact test. Normally distributed continuous variables were compared by Student t test. Time intervals were analyzed with the Mann-Whitney U test. Analyses were conducted using SAS version 9.13 (SAS Institute Inc, Cary, NC). Time to the occurrence of primary outcome in each treatment group was described using Kaplan-Meier curves, and the groups were compared using the log-rank test. A P value Յ0.05 was considered statistically significant. 1). The baseline characteristics of the patients were similar between the 2 groups ( Table 1 ). The proportion of high-risk patients defined by the TIMI investigators 26 (age Ͼ70 years, anterior myocardial infarction, or history of previous myocardial infarction) was 56.7% in patients assigned to heparin plus eptifibatide and 64.8% in patients assigned to heparin alone (Pϭ0.10). Data on end points at 30-day follow-up were available for all patients and data for the 6-month follow-up were available for all patients assigned to heparin plus eptifibatide and for 99.0% of patients assigned to heparin alone.
Initial Treatment Received
All patients received aspirin, clopidogrel, and heparin before catheterization. Eptifibatide was administered to all patients assigned to heparin plus eptifibatide; the first bolus was given before catheterization in 94.0%, and the duration of infusion averaged 16.2Ϯ5.0 hours after the procedure. In patients assigned to heparin alone, 9 patients (4.5%) were given abciximab and 6 patients (3.0%) were given eptifibatide during PCI.
Angiographic and Procedural Results
The results of the angiographic procedure are given in Table  2 . After coronary angiography, PCI was performed in 190 patients (94.5%) assigned to heparin plus eptifibatide and in 184 patients (92.4%) assigned to heparin alone. There was no difference in the initial TIMI flow grade between the 2 groups. After PCI, TIMI flow grade 3 was achieved in 93.5% of patients assigned to heparin plus eptifibatide and in 91.5% of patients assigned to heparin alone (Pϭ0.33). Seven patients (3.6%) in the eptifibatide group and 3 patients (1.5%) in the heparin-alone group were treated with bypass surgery within 24 hours of admission, and 1 patient in the eptifibatide group required emergency bypass surgery because primary PCI failed.
Clinical Results
At 30 days, the primary end point-the composite of death from any cause, recurrent myocardial infarction, or recurrent severe ischemia-was reached by 13 patients (6.47%) in the heparin plus eptifibatide group and 11 patients (5.53%) in the heparin-alone group (relative risk, 1.18; 95% CI, 0.52 to 2.70; Pϭ0.69; Table 3) . Similarly, at 6 months, there was no difference in the incidence of the primary end point between the 2 groups: 7.96% versus 7.11%, respectively, (relative risk, 1.13; 95% CI, 0.54 to 2.38; Pϭ0.75). The Kaplan-Meier curves of the cumulative incidence of the primary end point at 30 days and at 6 months are shown in Figure 2 . Post hoc analysis according to clinical, angiographic, and time-totreatment variables did not show any differences in the risk ratios for the incidence of the primary end point at 30 days among subgroups (Figure 3) .
The rates of stroke, congestive heart failure, and cardiogenic shock did not differ between the 2 groups at 30 days and at 6 months (Table 3) . Subsequent need for revascularization did not differ between the 2 groups. There was no difference between the 2 groups in the cardiac medications prescribed at hospital discharge and at 6 months (Table 4) .
Bleeding
During the initial hospitalization, when compared with patients assigned to heparin alone, the rates of TIMI bleeding (major or minor) were significantly higher in the patients assigned to heparin plus eptifibatide, 22.4% versus 14.6% (relative risk, 1.69; 95% CI, 1.01 to 2.83; Pϭ0.04). Two patients treated with dual antiplatelet therapy plus warfarin in the heparin-alone group experienced nonfatal intracranial hemorrhage after hospital discharge.
Discussion
The principal finding of our trial is that in patients pretreated with high-dose clopidogrel and referred for primary PCI, treatment with heparin plus eptifibatide, when compared with heparin alone, did not improve clinical outcomes. Furthermore, the incidence of bleeding was higher in patients assigned to heparin plus eptifibatide.
The ASSIST trial is the first to report on the use of eptifibatide in patients with STEMI pretreated with a 600-mg loading dose of clopidogrel before cardiac catheterization. Two other randomized trials that assessed the benefits of a glycoprotein IIb/IIIa inhibitors in this setting. 27, 28 The Bavarian Reperfusion AlternatiVes Evaluation 3 study examined the effect of abciximab versus placebo and found no difference in infarct size between groups as measured by MRI and no difference in death, reinfarction, target vessel revascularization, or stroke at 30 days. 27 The Ongoing Tirofiban In Myocardial infarction Evaluation 2 study reported that early administration of tirofiban was associated with improved ST-segment resolution but did not reduce the composite of death, reinfarction, or target vessel revascularization at 30 days nor have an impact on final TIMI perfusion grade or myocardial blush scores. 28 Five randomized trials have shown that abciximab improves clinical outcomes in patients treated with primary PCI. [5] [6] [7] [8] [9] However, patients enrolled in these trials were not Data are presented as meanϮSD or n (%).
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pretreated with high-dose thienopyridines before catheterization, and many did not receive a thienopyridine until after the procedure. Current data on the pharmacokinetics of clopidogrel in the context of STEMI remain limited. The bioavailability of clopidogrel may be restricted in these patients. 29 Studies that excluded patients with STEMI have shown that pretreatment with 300 mg of clopidogrel before PCI improves clinical outcomes. 19, 30 However, in the Clopidogrel for the Reduction of Events During Observation trial, the difference in clinical outcomes between placebo and clopidogrel was not significant until at least 15 hours of pretreatment. 30 In the Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty 2 study, when compared with the conventional 300-mg loading dose of clopidogrel, a 600-mg loading dose given 4 to 8 hours before PCI reduced periprocedural myocardial infarction. 31 Data are presented as n (%). CABG indicates coronary artery bypass grafting. *All events presented as chest discomfort with dynamic ECG changes and none as acute pulmonary edema, sustained ventricular arrhythmia, or hemodynamic instability.
†Repeat PCI of infarct-related artery or CABG after PCI.
Analysis from the Primary Angioplasty In Myocardial Infarction trials found that a thienopyridine given in the emergency department was associated with increased rates of TIMI grade 3 flow before PCI. 32 In a recent study, initial patency and clinical outcome were improved in patients undergoing primary PCI that received pretreatment with clopidogrel. 33 The clinical benefits of pretreatment with clopidogrel have also been reported in patients treated initially with fibrinolytic therapy, who subsequently required urgent PCI. 4 The high-loading dose of clopidogrel given to our patients before the procedure may account for the lack of clinical benefit with eptifibatide. Although many patients in the heparin-alone group may not have achieved maximal inhibition of platelet activity at the time of balloon inflation, the vulnerable period for abrupt vessel closure may have been abbreviated by administering high-dose clopidogrel before Other factors could have contributed to the observed lack of effect of eptifibatide on the primary end point. Our study was performed after the establishment of an integrated city-wide rapid response STEMI system, which resulted in relatively short ischemic time intervals. 34 A very high adherence to guidelines of medication during the entire study period may have also prompted a low event rate at follow-up. 35 Time to presentation Ͻ2 to 3 hours is critical to improve myocardial salvage and survival with reperfusion therapy. 36 The lack of benefit of abciximab before cardiac catheterization in the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events study was attributed to the long delay between symptom onset and initiation of therapy. 37 In our study, subgroup analysis demonstrated that even patients randomized within 180 minutes of symptom onset did not benefit from the addition of eptifibatide.
Bleeding is now reported as an independent predictor of 30-day mortality in patients with acute coronary syndromes. 38, 39 In the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction trial, anticoagulation with bivalirudin alone, when compared with heparin plus glycoprotein IIb/IIIa inhibitors, yielded significantly lower 30-day rates of major bleeding and net adverse clinical events. 40 In our study, bleeding rates were lower in the patients assigned to heparin alone, and this was achieved with peak activating clotting times that were substantially lower than that reported previously. 5, 6, 9, 37, 40 Our study has a few limitations. Because of the relatively small sample size, we may not have been able to discern a difference between the 2 treatment groups with respect to the primary end point because the CIs (0.52 to 2.70) do not exclude a reduction in event rate by as much as 48% with the use of heparin plus eptifibatide. In the era that preceded high clopidogrel loading doses, several studies designed with similar sample sizes were capable of showing a beneficial effect of adjuvant glycoprotein IIb/IIIa therapy. [5] [6] [7] The larger Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial found a relatively small treatment effect with abciximab compared with that of placebo. 9 However, in the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial, patients were randomized only after diagnostic angiography was performed and in the absence of specific angiographic exclusion criteria. We now estimate that given our results, it would require Ͼ20 000 patients to find a significant difference in our primary end point between the 2 treatment groups. The lack of improvement with the use of heparin plus eptifibatide, when compared with heparin alone, was unexpected, and the study was not powered to find such small difference in the clinical outcomes. Despite the use of open label eptifibatide in the study, it is unlikely that this had a significant impact on the results because the rate of crossover was Ͻ10%. Furthermore, an independent committee that was blinded to the treatment group adjudicated the events. Although acute pulmonary edema, sustained ventricular arrhythmia, and hemodynamic instability, which were components of the definition of recurrent severe ischemia, may be due to left ventricular dysfunction and not ischemia, all events adjudicated as severe recurrent ischemia were in patients presenting with recurrent chest pain associated with dynamic ECG changes. It cannot be argued that our patients were at low-risk, as 61% would be classified as high-risk by the TIMI investigators. 26 In conclusion, in patients with STEMI pretreated with high-dose clopidogrel before primary PCI, treatment with heparin plus eptifibatide, when compared with heparin alone, did not improve clinical outcomes and was associated with more bleeding complications. A large, multicenter, randomized trial would be necessary to determine the role of eptifibatide in primary PCI. Data are presented as n (%).
